Melbourne-founded health-technology company Heidi is moving beyond AI note-taking towards a wider clinical workflow platform, backed by a newly announced US$340 million financing package and a growing footprint in Australian hospitals. Its progress captures both the commercial promise of healthcare automation and the considerable safety and integration demands involved in putting software alongside clinicians.
The September financing comprises a US$100 million Series C equity round led by Blackbird and a separate US$240 million growth investment led by General Catalyst’s Customer Value Fund. Heidi said the equity transaction valued the company at US$900 million. Those are US-dollar figures, not Australian-dollar equivalents, and the two funding components have different characteristics: combining them as though both were venture equity would misstate the transaction.
From a clinician’s problem to a technology business
Heidi traces its origins to Melbourne in 2019, when doctor and co-founder Tom Kelly began working on technology designed to give healthcare workers more time with patients. Its founding leadership also includes finance co-founder Waleed Mussa and technology co-founder Yu Liu. Earlier work under the Oscer name centred on medical learning and clinical reasoning, an unusually direct route into the practical requirements of clinical software.
The founding problem was not simply a shortage of digital records. Clinicians increasingly enter the same information in multiple systems, prepare letters and referrals, review histories and finish documentation after consultations. Digital health systems can preserve important information without necessarily making the surrounding work simpler. Heidi’s proposition is that machine-assisted documentation can release time while keeping clinical judgement, responsibility and review with a qualified professional.
That positioning distinguishes the venture from a conventional transcription provider. Heidi’s software listens to a consultation where the necessary permissions have been obtained, drafts structured clinical notes and supports related administrative documents. The commercial buyer can be an individual practitioner, a practice group or a health system; the decision to buy involves workflow fit, privacy, clinician adoption, data handling and institutional procurement rather than the accuracy of a demonstration alone.
Evidence from Australian health services
Australian deployments provide the strongest test of the company’s home-market significance. In July 2026 Heidi announced a 12-month partnership with Cabrini Health following a four-week emergency-department pilot. The hospital said the trial indicated improvements in documentation time, patient throughput and staff experience. Those are reported pilot findings, not proof that the same effects will occur everywhere or that every site has entered a permanent deployment.
Cabrini’s emergency department receives about 25,000 presentations annually, according to the partnership announcement. That setting is operationally demanding: consultations are time-sensitive, patient details can change quickly and documentation must be available to other clinicians. A useful clinical assistant must therefore work during busy shifts without introducing inaccurate summaries, adding verification work or slowing the transfer of information.
Other company-reported Australian relationships include Monash Health, the Queensland Children’s Hospital and Health Service and a Metro South Health rollout announced in August. These examples indicate movement from individual clinician interest into system-level implementation. They should not be treated as interchangeable commercial arrangements: a pilot, technology partnership, staged rollout and permanent procurement contract carry different revenue certainty and implementation responsibilities.
What the financing actually changes
Heidi said its US$100 million Series C was led by existing Australian investor Blackbird, with participation from other investors including Phoenix Court, Point72 Private Investments and Headline. The accompanying General Catalyst investment is intended to support growth and go-to-market capacity. The structure highlights how financing a healthcare platform involves more than building software: distribution, training, technical support, regulatory work and enterprise integration all become more expensive with scale.
The company reported that its technology was being used across 2.8 million patient visits each week in 190 countries at the time of the September announcement. That figure is a company-reported usage measure and should not be equated with paid seats, audited recurring revenue or the number of distinct customers. Usage at that scale is commercially significant, but the next investor question is how widely and sustainably it converts into contracted institutional adoption.
Its approach combines individual clinician access with larger organisational deployments. The first route can create broad awareness at relatively low sales cost, while the second may offer more durable contracts and more complex integration requirements. Enterprise buyers need agreements on access controls, information retention, liability, cybersecurity, training and compatibility with the record systems clinicians already use. A popular tool cannot assume that hospitals will approve it through ordinary software procurement.
Clinical AI faces a different accountability test
Healthcare documentation is not an ordinary productivity category. A plausible-looking error about an allergy, medicine, diagnosis or clinical plan can have consequences beyond wasted staff time. Clinicians must be able to inspect and correct outputs, and organisations need processes for consent, information security and incident management. The more Heidi moves towards what it describes as supervised action beyond the consultation, the more consequential these safeguards become.
The company describes its future product as an AI Care Partner that supports clinical work beyond taking notes. That ambition opens opportunities in follow-up communications, scheduling, evidence retrieval and workflow coordination, but raises additional questions about when automation should act and when a person must authorise the next step. The distinction matters to Australian hospital executives evaluating both productivity and clinical governance.
Competition is also formidable. Large electronic medical record vendors, specialised ambient-documentation providers and major technology companies are investing in similar capabilities. Heidi’s Australian clinical relationships and early adoption give it useful evidence of market fit, but not a protected position. Its ability to retain users will depend on accuracy, workflow convenience, integrations, pricing and trust as competing services improve.
An Australian venture with an international operating model
Austrade has documented Heidi’s expansion into Hong Kong as a gateway to North Asia, including agreements with healthcare and education organisations. Overseas demand is a genuine part of the business story, but its Australian identity remains material: the venture was founded in Melbourne, has attracted Australian growth capital and is testing its product with Australian public and private health providers.
That connection matters to the domestic technology sector. Australian clinicians can provide a sophisticated testing environment for tools that need to work across specialties and complex care settings. At the same time, Australian hospitals can benefit from local implementation expertise and from the ability to influence a fast-growing supplier’s roadmap, provided procurement teams demand evidence of outcomes rather than simply accepting global adoption claims.
The next chapter will not be decided by a funding headline alone. Heidi must show that clinical teams keep using the product after an initial trial, that large deployments improve measurable operations without compromising safety, and that institutions will pay for those improvements. For a Melbourne-founded company seeking global scale, the commercial prize is large; the obligation to prove reliability inside Australian healthcare is equally substantial.
Sources: Heidi, Series C and growth financing, 22 September 2026; Heidi and Cabrini Health, July 2026; Heidi corporate media information; Austrade, 10 August 2026; Heidi funding and customer information. Featured image: illustrative stock photograph, Vitaly Gariev / Unsplash; not a Heidi team member or customer.
